Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.0K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

86
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
86
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

86
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
86

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

The oncologist·2026
Same author

Response assessment in [177Lu]PSMA: where do we stand?

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2026
Same author

A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer.

BJU international·2026
Same author

Corrigendum to "International multicentric validation of a novel T classification system for cancer of the nasal vestibule"[Eur J Cancer 235 (2026), 116245].

European journal of cancer (Oxford, England : 1990)·2026
Same author

Corrigendum to "Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer" [Radiother. Oncol. 216 (2026) 111385].

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

ESR Innovation in Focus: Future PET radiotracers in oncology.

European radiology·2026
Same journal

Invited Commentary: Postdeployment Monitoring of AI in Radiology: Beyond the Test Set.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026
Same journal

Rosai-Dorfman Disease: Imaging and Updates.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026
Same journal

Spectrum of Breast Sarcomas with Radiologic-Pathologic Correlation.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026
Same journal

Postdeployment Monitoring and Surveillance Methods, Guidelines, and Possibilities for AI in Radiology.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026
Same journal

Clinical Correlation for Imaging of Left Ventricular Assist Devices.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026
Same journal

Invited Commentary: Three-Piece Inflatable Penile Prosthesis: Imaging Insights Beyond the Operating Room.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K

PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects.

Laszlo K Szidonya1, Tara D Barwick1, Amarnath Challapalli1

  • 1From the Department of Diagnostic Radiology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, L340, Portland, OR 97239 (L.K.S., D.B., N.M.); Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom (A.C.); and Department of Radiology, Charing Cross Hospital, Imperial College Health Care NHS Trust, London, United Kingdom (T.D.B., M.N., A.E.).

Radiographics : a Review Publication of the Radiological Society of North America, Inc
|November 21, 2024
PubMed
Summary
This summary is machine-generated.

Lutetium 177 (177Lu)-PSMA radioligand therapy offers a promising new treatment for metastatic castration-resistant prostate cancer. This approach, utilizing prostate-specific membrane antigen (PSMA) targeting, improves survival and quality of life.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.4K

Related Experiment Videos

Last Updated: Jun 7, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.4K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Therapy

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) poses significant treatment challenges.
  • Prostate-specific membrane antigen (PSMA) is a key target for advanced prostate cancer therapies.
  • 177Lu-PSMA radioligand therapy represents an emerging treatment modality for mCRPC.

Purpose of the Study:

  • To review the current landscape of PSMA-based radioligand therapy for mCRPC.
  • To discuss patient selection, treatment administration, and response assessment.
  • To highlight future directions in PSMA-targeted prostate cancer treatment.

Main Methods:

  • Review of current practices in 177Lu-PSMA radioligand therapy administration and dosing.
  • Focus on eligibility criteria and the role of PSMA PET imaging for patient selection and monitoring.
  • Discussion of response assessment criteria and post-therapy imaging.

Main Results:

  • 177Lu-PSMA-617 approval, based on the VISION trial, demonstrated improved overall survival and quality of life in mCRPC patients.
  • PSMA expression assessment via PSMA PET is critical for treatment eligibility.
  • Current practices, side effects, and the value of post-therapy imaging are discussed.

Conclusions:

  • 177Lu-PSMA radioligand therapy is a significant advancement in mCRPC treatment.
  • Further validation of response assessment criteria using PSMA PET is needed.
  • Ongoing trials explore new PSMA agents, earlier treatment stages, and combination therapies for prostate cancer.